South China Venture Capital

YoungEn Technology is an automation equipment company that specializes in providing automated, intelligent production equipment solutions.

Yhope Tech is a high-tech company that designs, researches, develops, consults, and sells solutions for industrial automation, interconnection, and intelligent manufacturing.

Yuewei Medical specializes in the development of interventional medical devices for cardiac surgery. The company is committed to creating innovative products that enhance the entire process of medical device and equipment solutions in this field. Its offerings include a range of advanced devices such as coronary artery bypass graft cardiac fixators, intraoperative ultrasonic flow detectors, left ventricular assist devices, and coronary anastomosis auxiliary systems. By focusing on the transformation and development of these technologies, Yuewei Medical aims to advance the medical device industry and provide high-quality solutions for cardiac surgical procedures.

Presheng New Materials is a high-end semiconductor polishing solution provider. The company has extensive technical knowledge of high-end abrasives. Prisheng focuses on the research and development of high-end alumina polishing fluids, polishing abrasives, and other goods. Provider of cost-effective local solutions for third-generation compound semiconductor polishing.

Sanhydro Technology focuses on the design, sales, and production of intelligent integrated hydrogen fuel cell stacks molded, graphite bipolar plates.

IDT Micro is a microelectronics technology company that specializes in manufacturing and developing automotive-grade analog chips and power switching devices.

Namei Semiconductor develops semiconductor probe station technology, and its devices are mostly utilized in the CP testing process following wafer manufacturing and prior to packing.

Zentek is a manufacturer of high-end silicone materials used for research and development. The company operates in eight main application areas: automotive electronics, consumer electronics, power batteries, packaging, industry, medical care, semiconductor wafer processing, and chip packaging.

Sanshiyuan Technology is engaged in the R&D, production, and sale of passive optical fiber devices. Its main products include: optical fiber circulators, high-end passive integrated devices, high-reliability, cost-effective wavelength division multiplexers, and high-reliability cost-effective optical fiber isolator, MEMS optical switch, product features are miniaturization and integration.

Avant Semi is a high-tech company specializing in the development and manufacturing of semiconductor front-end measurement and testing equipment. The company's products are designed for use in semiconductor production, enabling effective measurement of epitaxial layers, photoresist thickness, and element concentration. Avant Semi's equipment can be integrated with ultra-high vacuum systems or specialized chambers, allowing semiconductor manufacturing enterprises to enhance efficiency while reducing costs associated with use and maintenance. Through its innovative solutions, Avant Semi supports the advancement of the semiconductor industry.

Huixin Bio is a researcher and developer of liquid biopsy diagnostic products. It focuses on developing world-leading biomedical technologies and products. It offers an automatic exosome purification system.

Zheta Technology offers high-end manufacturing digital transformation services to help manufacturing companies complete intelligent upgrades, using deeply integrated Big Data, AI algorithms, and industry know-how. Zheta Technology assists customers in increasing yield rate, equipment utilization rate, and production capacity, as well as completing the transparent management of the next generation of digital factories.

Bangxin Semiconductor is dedicated to delivering cost-effective semiconductor equipment for the integrated circuit and pan-semiconductor sectors. The company focuses on four primary fields: compound semiconductors, integrated circuits, packaging and testing, and panel industries.

Liufang Tech specializes in the development and production of silicon carbide (SiC) technology, primarily focusing on its application in the semiconductor industry. The company offers a range of products, including chemical vapor deposition (CVD) silicon carbide coatings, graphite components, and tantalum carbide-coated products. These materials are pivotal in the production of semiconductor chips, particularly in sectors such as LED, SiC, gallium nitride (GaN), and monocrystalline silicon epitaxy. By providing hard and high-temperature resistant materials, Liufang Tech aims to enhance the performance and durability of semiconductor applications for its clients.

Immunowake is a biotechnology company dedicated to developing innovative therapies for patients who do not respond to current immunotherapies. The company aims to enhance the body's immune response against cancer by developing a universal cancer vaccine that generates safer and more effective bi-specific antibodies. By focusing on activating antigen-specific T-cells, Immunowake seeks to "wake up" the immune system, allowing it to identify and eliminate cancer cells more effectively. This approach not only strives to improve the efficacy of cancer treatments but also aims to reduce the associated toxicity for patients, ultimately enhancing their overall treatment experience.

Wuxi Xinxiang is a semiconductor factory production automation CIM solution and services provider. They focus on intelligent automation production solutions and services in the field of wafer manufacturing, packaging and testing.

Accro Bioscience is a biotechnology company that develops innovative small molecule drugs aimed at treating inflammatory and autoimmune diseases, as well as cancer. The company specializes in researching the molecular mechanisms of regulated cell death, including necroptosis, pyroptosis, and ferroptosis. By understanding these processes and their roles in disease pathogenesis, Accro Bioscience seeks to enhance current therapeutic standards in targeted disease areas, contributing to advancements in treatment options for patients.

Innoforce Pharmaceuticals Co., Ltd is a biopharmaceutical company based in Hangzhou, China, founded in 2018. The company specializes in the development and commercialization of innovative biomedicines, including cell and gene therapies, medicines, and antibodies. Innoforce also operates biologic process development laboratories and offers end-to-end contract development and manufacturing services (CDMO) tailored to support biotech enterprises in their research and development and manufacturing efforts. Through its comprehensive services, Innoforce aids clients in bringing their biopharmaceutical products to market efficiently.

Inmagene Biopharmaceuticals Co. Ltd. is a Shanghai-based biopharmaceutical company founded in 2019, specializing in the research and pre-clinical development of therapies for immunology-related diseases. The company focuses on creating innovative drug candidates that address unmet medical needs globally, employing a strategy known as "Borderless Innovation." Inmagene has developed a diverse pipeline, including IMG-020, a protein drug designed to target IL-17A, which utilizes a combination of Affibody's protein therapeutics platform and Albumod technology to enhance potency and extend half-life. In addition to IMG-020, the company boasts several clinical-stage assets and multiple preclinical candidates aimed at improving pharmacokinetic and pharmacodynamic properties, safety profiles, and dosing convenience for patients. With additional offices in Hangzhou and Beijing, Inmagene is dedicated to advancing drug development through cutting-edge technology and a commitment to global collaboration in the fight against immunological diseases.

Innoforce Pharmaceuticals Co., Ltd is a biopharmaceutical company based in Hangzhou, China, founded in 2018. The company specializes in the development and commercialization of innovative biomedicines, including cell and gene therapies, medicines, and antibodies. Innoforce also operates biologic process development laboratories and offers end-to-end contract development and manufacturing services (CDMO) tailored to support biotech enterprises in their research and development and manufacturing efforts. Through its comprehensive services, Innoforce aids clients in bringing their biopharmaceutical products to market efficiently.

Cullgen Inc. is a biopharmaceutical company based in San Diego, California, founded in 2018. The company specializes in the development of innovative small molecule therapeutics aimed at treating diseases that currently lack effective therapeutic options, including cancer, inflammatory, and autoimmune diseases. Utilizing its proprietary uSMITE™ platform, Cullgen employs targeted protein degradation technology to selectively degrade disease-causing proteins, even those previously deemed undruggable. This approach enables the creation of first-in-class new chemical entities, providing scientists with novel methodologies for drug discovery and potentially transforming treatment paradigms for difficult-to-treat conditions.

Drug Farm Inc. is a biotech company based in Shanghai, China, engaged in the development of innovative drugs and technologies for metabolic diseases such as obesity, diabetes, and fatty liver, as well as targeting innate immunity for conditions like HBV, cancer, and autoimmune diseases. The company employs its unique IDInVivo platform, which integrates advanced genetics and artificial intelligence to identify novel drug targets through genetic screens in living animals with intact immune systems. By leveraging various AI methodologies, including supervised learning, active learning, and reinforcement learning, Drug Farm aims to accelerate the medicinal chemistry development process, ultimately striving to deliver first-in-class therapeutic solutions to the healthcare industry.

Inmagene Biopharmaceuticals Co. Ltd. is a Shanghai-based biopharmaceutical company founded in 2019, specializing in the research and pre-clinical development of therapies for immunology-related diseases. The company focuses on creating innovative drug candidates that address unmet medical needs globally, employing a strategy known as "Borderless Innovation." Inmagene has developed a diverse pipeline, including IMG-020, a protein drug designed to target IL-17A, which utilizes a combination of Affibody's protein therapeutics platform and Albumod technology to enhance potency and extend half-life. In addition to IMG-020, the company boasts several clinical-stage assets and multiple preclinical candidates aimed at improving pharmacokinetic and pharmacodynamic properties, safety profiles, and dosing convenience for patients. With additional offices in Hangzhou and Beijing, Inmagene is dedicated to advancing drug development through cutting-edge technology and a commitment to global collaboration in the fight against immunological diseases.

CARsgen Therapeutics, Ltd. is a clinical-stage immunotherapy company based in Shanghai, China, focused on developing chimeric antigen receptor T-cell (CAR-T) therapeutics for various cancers, including liver, lung, stomach, and brain cancers. The company specializes in CAR-T technology that enables T cells to target and destroy cancer cells by recognizing specific cell surface proteins. Notably, CARsgen’s therapies are designed to treat late-stage hepatocellular carcinoma (HCC) and lung squamous cell carcinoma. The company has also made significant advancements in clinical trials, having completed the world's first dose-ascending injection tests for HCC and exclusive tests for glioblastoma multiforme (GBM) in China. CARsgen collaborates with institutions such as the Shanghai Cancer Institute and Shanghai Renji Hospital, and is supported by prominent venture capital funding, positioning it to introduce innovative cancer treatments both in China and globally.

Shanghai Zhuishi Technology Co., Ltd., founded in 2019, specializes in the research and development of low-speed autonomous driving technology. Based in Shanghai, China, the company focuses on creating autonomous driving systems and solutions tailored for automotive manufacturers. Zhuishi Technology aims to advance the capabilities of self-driving vehicles, contributing to the evolution of transportation through innovative technology.

Jinfang Pharmaceutical is focused on R&D and drug development from small molecule drug pipelines to diversified cutting-edge therapies.

GenFleet Therapeutics, based in Shanghai, China, is a biotechnology company focused on the research and development of therapeutic molecules aimed at cancer treatment. Founded in 2017, the company specializes in creating innovative molecular pharmaceuticals and antibody drugs that target various cancer systems. GenFleet's work involves developing signal transduction regulators, tumor microenvironment modulators, and transcription factors, among other therapeutic agents. The company's mission is to provide effective medical solutions that can reactivate tumor-specific immune responses and enhance the body's own immune system in combating cancer. With a commitment to advancing cancer therapies, GenFleet serves both domestic and international markets.

Ipoweru.cn is an online education platform based in Beijing, China, founded in 2017. The company specializes in providing personalized educational services for schools, including recruitment and a variety of online courses aimed at preparing students for college entrance examinations. Additionally, Ipoweru.cn offers streaming class videos and comprehensive talent management solutions, which assist local education bureaus in navigating the complexities of the new college entrance examination system with multiple admission backgrounds.

EpimAb Biotherapeutics is a biopharmaceutical company based in Shanghai, China, focused on the research and development of novel bispecific antibody therapeutics. Utilizing its proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform, the company creates bispecific molecules that possess antibody-like properties. This innovative approach aims to address the challenges associated with developing effective bi-specific antibodies, which are engineered from two different monoclonal antibodies to combine their therapeutic features into a single entity. These bispecific antibodies hold promise for treating various life-threatening conditions, particularly in immuno-oncology, by offering new therapeutic options. Despite the potential benefits of bi-specific antibodies, many candidates face hurdles in development due to issues related to their binding properties, pharmacokinetics, and production costs. EpimAb Biotherapeutics is positioned to contribute to the growing need for advanced bi-specific therapeutics in the pharmaceutical industry.

Apollomics, Inc. is an emerging life sciences company based in Foster City, California, focused on developing innovative oncology therapies aimed at targeting the growth and proliferation of cancer cells. Founded in 2016, the company’s pipeline includes several development-stage assets, such as CBT-101, an oral agent that targets the epithelial to mesenchymal transition pathway associated with various tumors, and CBT-102, which inhibits the MAP Kinase pathway and angiogenesis through its effects on specific receptors. Additionally, Apollomics is advancing monoclonal antibodies CBT-501 and CBT-502, which target the PD-1 and PDL-1 membrane receptors, respectively, to enhance the immune response against cancer. By combining immune-based strategies with targeted therapies, Apollomics aims to develop novel treatments that can effectively combat cancer.

Daily Shakes is a block chain social service platform that provides users with interactive content sharing.

HUAHUI TECHNOLOGY, based in Shenzhen, China, specializes in designing and developing quality management and improvement solutions for enterprises. Founded in 2012, the company provides a range of software and cloud computing services tailored to customer needs across various sectors. Its offerings include intelligent visualization, multi-dimensional data mining, and analysis tools that facilitate resource utilization and informed decision-making. HUAHUI TECHNOLOGY's platform enables clients to systematically manage their production processes by quantifying product quality data, generating quality check reports, and providing defect tracking and early warning services. The company's focus on customized and modular solutions helps businesses build effective information quality management systems, ensuring convenience and safety in operational processes.

Wuxian Zhitou focuses on performing time series classification and prediction in ETF and mutual fund markets using the machine learning paradigm.

LEADRIVE is a technology company specializing in the research, development, production, and sales of drive solutions for new energy vehicles, as well as high-performance power semiconductor modules. The company designs and manufactures advanced motor controllers and proprietary power modules that have been adopted by over ten leading automotive manufacturers and Tier-1 suppliers for mass production. LEADRIVE is also engaged in enhancing the localization of power semiconductor modules, with ongoing certification processes for silicon carbide modules and electronic controls. Additionally, the company invests in innovative energy solutions, including wind, solar, and energy storage systems. In collaboration with Rohm Semiconductor from Japan, LEADRIVE has established a joint laboratory to develop various silicon carbide modules, focusing on improving efficiency through comprehensive simulation, testing, and development processes that span from device-level to vehicle-level applications.

Chongxin Chongwu is a professional pet health solutions and service provider.

Tian Jian is a medical technology company that specializes in developing medical information systems and software tailored for hospitals. The company focuses on creating digital solutions that enhance hospital operations, including medical cost management, patient services, and decision-making processes. By providing these innovative tools, Tian Jian enables healthcare facilities to digitize their operations and improve overall efficiency. Additionally, the company addresses customer inquiries through various channels, including phone, email, and online applications, ensuring effective communication and support for its clients in the healthcare sector.

Zhuhai Biyao Technology Co., Ltd. operates an online e-commerce platform that connects consumers directly with quality manufacturers. Founded in 2014 and based in Zhuhai, China, the company offers a diverse range of products including accessories, cosmetics, apparel, furniture, and footwear. Biyao's platform aims to streamline the shopping experience by allowing customers to access high-quality products from renowned designers and manufacturers at factory prices, effectively eliminating intermediaries. This direct-to-consumer approach enhances product availability and affordability for customers.

Shaanxi Xifeng Liquor is a liquor-producing firm. They serve collector's editions: the colorful Xifeng wine series, the sea of wine aging series, the old green bottle series, the six-year and fifteen-year series, the Huashan on Sword series, and the national flower porcelain series. The work's main theme is to insist on putting equal focus on brand promotion and product sales.

sungoal provides exhibition service for new energy automobile and home building materials.